Company Description
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome.
It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection.
Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation.
In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis.
Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease.
The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015.
Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jun 26, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 233 |
| CEO | Eric D. Shaff M.B.A. |
Contact Details
Address: 200 Sidney Street Cambridge, Massachusetts 02139 United States | |
| Phone | 617 945 9626 |
| Website | serestherapeutics.com |
Stock Details
| Ticker Symbol | MCRB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001609809 |
| CUSIP Number | 81750R102 |
| ISIN Number | US81750R1023 |
| Employer ID | 27-4326290 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eric D. Shaff M.B.A. | President, Chief Executive Officer and Director |
| Dr. Lisa von Moltke M.D. | Executive Vice President and Chief Medical Officer |
| Dr. Teresa L. Young Ph.D., R.Ph. | Executive Vice President and Chief Commercial and Strategy Officer |
| Marella Thorell | Executive Vice President and Chief Financial Officer |
| Dr. David S. Ege Ph.D. | Executive Vice President and Chief Technology Officer |
| Dr. Matthew R. Henn Ph.D. | Executive Vice President and Chief Scientific Officer |
| Carlo Tanzi Ph.D. | Investor Relations Officer |
| Thomas J. DesRosier Esq., J.D. | Chief Legal Officer, Executive Vice President and Secretary |
| Caroline Holda | Assistant General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | 8-K | Current Report |
| Apr 8, 2024 | 8-K | Current Report |
| Apr 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 5, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2024 | 10-K | Annual Report |
| Mar 5, 2024 | 8-K | Current Report |
| Feb 26, 2024 | 8-K | Current Report |
| Feb 23, 2024 | PRE 14A | Other preliminary proxy statements |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |